Nassir Marrouche, HRS 2019 – the CASTLE-AF Trial
Dr Nassir Marrouche (Executive Director, CARMA Center, University of Utah, Salt Lake City, UT, USA) spoke to us at Heart Rhythm 2019 on the ablation outcomes from the Catheter Ablation vs. Standard Conventional Therapy in Patients with Left Ventricular Dysfunction and Atrial Fibrillation (CASTLE AF) trial, along with the current unmet needs in catheter ablation and his highlights from the meeting.
Filmed at Heart Rhythm 2019, San Francisco, CA, USA.
Speaker’s Disclosures: Nassir Marrouche has received consultancy fees from Abbott, Biosense Webster, Biotronic, Boston Scientific, Marrek Inc., Medtronic, Preventice and Vytronus, and received research grants from Abbott, Biosense Webster, Biotronic, Boston Scientific, GE Healthcare, Siemens and Vytronus. He has company interest in Marrek Inc. and Cardiac Design.
1. What were the key findings of the Catheter Ablation vs. Standard Conventional Treatment in Patients with LV Dysfunction and AF (CASTLE-AF) trial? (0:06)
2. How should the benefits shown in CASTLE-AF, including mortality reduction and quality of life improvement, influence patient management and current practice in atrial fibrillation and heart failure? (1:08)
3. What are your highlights from Heart Rhythm 2019? (2:16)
4. What are the current unmet needs in catheter ablation? (3:34)
touchCARDIO.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via free-to-access content in multimedia formats.
Share this Video
Related Videos In Atrial Fibrillation
Bruce Wilkoff, EHRA 2023: The AdaptResponse trial, synchronized left ventricular pacing for heart failure with left bundle branch block
The AdaptResponse trial was designed to assess two methods of restoring resynchronization to the heart in patients with heart failure with left bundle branch block. In this touchCARDIO interview, we speak with Dr Bruce Wilkoff (Cleveland Clinic, Cleveland, OH, USA) to discuss the design of the AdaptResponse trial, the outcomes as well as the clinical […]
Bruce Wilkoff, EHRA 2023: An overview of cardiac resynchronization therapy for patients with heart failure
Cardiac resynchronization therapy is designed to restore the electrical activation in a more natural way in patients with heart failure. In this touchCARDIO interview, we speak with Dr Bruce Wilkoff (Cleveland Clinic, Cleveland, OH, USA) to discuss the treatment paradigm with focus on cardiac resynchronization therapy for patients with heart failure. Bruce Wilkoff presented an […]
Søren Zöga Diederichsen, EHRA 2023: NT-proBNP as a tool for atrial fibrillation screening, post hoc analysis of the LOOP study
Recently it has been shown that NT-proBNP may be a useful tool for finding people with an increased risk of atrial fibrillation and stroke. In this touchCARDIO interview, we speak with Dr Søren Zöga Diederichsen (Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark) to discuss the post hoc analysis of the LOOP study. The abstract entitled ‘Atrial […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!